Open AccessPancreatic secretory trypsin inhibitor: More than a trypsin inhibitor
Author(s) -
Gai-Ping Wang,
XU Cun-shuan
Publication year - 2010
Publication title -
world journal of gastrointestinal pathophysiology
Language(s) - English
Resource type - Journals
ISSN - 2150-5330
DOI - 10.4291/wjgp.v1.i2.85
Subject(s) - trypsinogen , psti , trypsin , protease inhibitor (pharmacology) , trypsin inhibitor , serine protease , medicine , serine proteinase inhibitors , kunitz sti protease inhibitor , pancreatitis , protease , pancreas , biochemistry , microbiology and biotechnology , enzyme , biology , immunology , gene , restriction enzyme , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load
Kazal-type serine protease inhibitor is one of the most important and widely distributed protease inhibitor families. Pancreatic secretory trypsin inhibitor (PSTI), also known as serine protease inhibitor Kazal type I(SPINK1), binds rapidly to trypsin, inhibits its activity and is likely to protect the pancreas from prematurely activated trypsinogen. Therefore, it is an important factor in the onset of pancreatitis. Recent studies found that PSTI/SPINK1 is also involved in self-regulation of acinar cell phagocytosis, proliferation and growth of a variety of cell lines. In addition, it takes part in the response to inflammatory factor or injury and is highly related to adult type II citrullinemia.